Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.
Publication
, Journal Article
Bal, S; Malek, E; Kansagra, A; Usmani, SZ; Vij, R; Godby, KN; Cornell, RF; Kang, Y; Umyarova, E; Giri, S; Chhabra, S; Liedtke, M; Hari, P ...
Published in: Leukemia
March 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Leukemia
DOI
EISSN
1476-5551
Publication Date
March 2022
Volume
36
Issue
3
Start / End Page
877 / 880
Location
England
Related Subject Headings
- Treatment Outcome
- Progression-Free Survival
- Multiple Myeloma
- Middle Aged
- Male
- Immunology
- Humans
- Female
- Benchmarking
- Antineoplastic Combined Chemotherapy Protocols
Citation
APA
Chicago
ICMJE
MLA
NLM
Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., … Costa, L. J. (2022). Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia, 36(3), 877–880. https://doi.org/10.1038/s41375-021-01471-3
Bal, Susan, Ehsan Malek, Ankit Kansagra, Saad Z. Usmani, Ravi Vij, Kelly N. Godby, Robert F. Cornell, et al. “Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.” Leukemia 36, no. 3 (March 2022): 877–80. https://doi.org/10.1038/s41375-021-01471-3.
Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022 Mar;36(3):877–80.
Bal, Susan, et al. “Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.” Leukemia, vol. 36, no. 3, Mar. 2022, pp. 877–80. Pubmed, doi:10.1038/s41375-021-01471-3.
Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, Chhabra S, Liedtke M, Callander NS, Hari P, Kumar S, Costa LJ. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022 Mar;36(3):877–880.
Published In
Leukemia
DOI
EISSN
1476-5551
Publication Date
March 2022
Volume
36
Issue
3
Start / End Page
877 / 880
Location
England
Related Subject Headings
- Treatment Outcome
- Progression-Free Survival
- Multiple Myeloma
- Middle Aged
- Male
- Immunology
- Humans
- Female
- Benchmarking
- Antineoplastic Combined Chemotherapy Protocols